October 7, 2020

End Duchenne Tour 2020: Virtual Tour Stop in Portland

End Duchenne Tour 2020: Virtual Tour Stop in Portland, OR On Saturday, September 12, we spent the morning with the Duchenne community in Portland, Oregon and the surrounding region for another End Duchenne [Remote] Tour…

Learn More

October 6, 2020

First Results from PPMD/Nationwide Carrier Study – Evidence of Cardiomyopathy by Exercise & Cardiac MRI

For females living with dystrophinopathy (the spectrum of diseases caused by mutations in the DMD gene), the disorder has not been historically characterized effectively. To address this need, PPMD provided a grant to Nationwide Children’s…

Learn More

October 6, 2020

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne

Today, we are disappointed to learn that Santhera announced its decision to discontinue development of its Phase 3 SIDEROS study with Puldysa® (idebenone) in Duchenne. Santhera will stop the SIDEROS trial (including extension) and participants…

Learn More

October 2, 2020

Catabasis Shares October 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter which includes information from their presentations at the Congress of the World Muscle Society. The Phase 3 PolarisDMD trial and GalaxyDMD open-label extension trial…

Learn More

October 1, 2020

Coach To Cure MD: Season 12 Is Underway!

It’s the start of the football season and we are excited to kick off this year’s 12th Annual Coach To Cure MD! Although we would normally host our annual event on the last Saturday of September,…

Learn More

October 1, 2020

Pfizer Receives FDA Fast Track Designation for PF-06939926 Investigational Gene Therapy

Pfizer Inc. announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne has received Fast Track designation from the FDA. PF-06939926 is currently being evaluated to determine the safety and efficacy of…

Learn More

October 1, 2020

FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

PPMD is delighted to learn that the FDA has lifted the hold on Solid Biosciences’ IGNITE-DMD clinical trial for their gene therapy product (SGT-001) delivering a micro-dystrophin transgene via AAV9. Solid has worked diligently to…

Learn More

September 28, 2020

Catabasis Presents Information On Edasalonexent At 25th International Congress Of The World Muscle Society

Catabasis Pharmaceuticals today shared information on the edasalonexent program in Phase 3 development for Duchenne in poster presentations at the Virtual 25th International Congress of the World Muscle Society. The posters include new preclinical research…

Learn More

September 28, 2020

Sarepta Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001 Gene Therapy

PPMD is excited to share today’s announcement from Sarepta Therapeutics regarding two-year follow up results from four clinical trial participants who received SRP-9001 (AAVrh74.MHCK7.micro-dystrophin). Results presented at the Virtual 25th International Congress of the World…

Learn More

September 24, 2020

WATCH: Resiliency in Results – What We Learn When Trials Are Terminated (Webinar Recording)

No other community knows the importance of resiliency like the Duchenne community, as highlighted by our communal commitment to ensure that all people living with Duchenne have access to safe, accessible therapies. Clinical trials are…

Learn More